Skip to Content
Merck
All Photos(1)

Documents

O-024

Supelco

Olanzapine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H20N4S
CAS Number:
132539-06-1
Molecular Weight:
312.43
EC Number:
200-835-2
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)

Related Categories

General description

An analytical reference standard for use in LC/MS or GC/MS applications including clinical toxicology analysis or therapeutic drug monitoring. Marketed under the trade name Zyprexa®, olanzapine is an atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder.

Application

  • Metabolic impact of Olanzapine in bipolar disorder: A network meta-analysis of randomized-controlled trials assessed the metabolic effects of antipsychotics and mood stabilizers, including Olanzapine, in patients with bipolar disorder, providing insights into its pharmacodynamic properties and implications for treatment optimization (Kong et al., 2024).
  • Machine learning in schizophrenia research: Olanzapine′s effectiveness was evaluated through a systematic review employing machine learning to predict violent behaviors in schizophrenia spectrum disorders. This study underscores the relevance of antipsychotic treatment profiling in enhancing patient-specific therapeutic strategies (Delvecchio et al., 2024).
  • Solubility and bioavailability enhancement: Research focused on the evaluation of polymeric matrices for loading poorly water-soluble drugs, like Olanzapine, into mesoporous silica. This study advances the development of more effective and bioavailable oral liquid formulations of Olanzapine (Barmpalexis et al., 2024).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zyprexa is a registered trademark of Eli Lilly and Co.

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Jean A Milstein et al.
PloS one, 8(2), e57308-e57308 (2013-02-26)
Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of
Stephen M Stahl et al.
The Journal of clinical psychiatry, 74(5), 507-515 (2013-04-02)
The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. Patients who completed a 6-week, double-blind
Chantal Henry et al.
BMC psychiatry, 13, 79-79 (2013-03-21)
One of the major issues in clinical practice is the accurate differential diagnosis between mixed states and depression, often leading to inappropriate prescriptions of antidepressants in mixed states, and as a consequence, increasing the risk of manic switch and suicide.
A case of atypical antipsychotic-induced somnambulism: a class effect.
Yael Dagan et al.
The Journal of clinical psychiatry, 74(4), 370-370 (2013-05-10)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service